Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Microbial anti-inflammatory molecule (MAM) is a 15 kDa protein produced by the commensal gut bacterium Faecalibacterium prausnitzii, which is one of the most abundant species in the healthy human microbiota [2, 6, 15]. MAM serves as a key effector molecule that mediates the anti-inflammatory effects of the bacterium, primarily by inhibiting the NF-kappaB signaling pathway in intestinal epithelial cells [1, 2, 3, 15]. This inhibition leads to a significant reduction in the production of pro-inflammatory cytokines, such as Interleukin-8 (IL-8), and helps to suppress Th1, Th2, and Th17 immune responses [4, 6, 11]. Furthermore, MAM plays a crucial role in maintaining and restoring the intestinal barrier by upregulating tight junction proteins like Zonula occludens-1 (ZO-1), which prevents the translocation of pathogens and toxins [1]. In clinical contexts, a depletion of Faecalibacterium prausnitzii and its associated MAM protein is a hallmark of dysbiosis in patients with Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases (IBD) [2, 5, 6, 11]. Research has also linked MAM deficiency to metabolic disorders such as type 2 diabetes and potentially neurodegenerative conditions like Parkinson's disease [1, 15]. Therapeutic strategies currently under investigation include the administration of recombinant MAM protein, MAM-derived peptides, or engineered "live biotherapeutic" probiotics, such as Lactococcus lactis, designed to deliver the MAM gene directly to the intestinal mucosa [2, 3, 4, 6]. These approaches aim to restore gut homeostasis and alleviate chronic inflammation by mimicking the natural protective mechanisms of the commensal microbiota [5, 15].
Inhibition of the NF-kappaB signaling pathway and upregulation of tight junction proteins (e.g., ZO-1) to restore intestinal barrier integrity and reduce pro-inflammatory cytokine secretion [1, 2, 3, 6, 15].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbial anti-inflammatory molecule (MAM) (MAM).